全口无牙颌应用种植固定修复后的咬合力分布研究

目的探讨全口无牙颌患者应用种植固定修复后的咬合力分布特点。方法选择15例全口无牙颌应用种植固定修复的患者作为实验组,15例具有天然牙列的实验者作为对照组,采用咬合力测定仪（FPD-705）测定口腔内的咬合力以及前牙区、双尖牙区和磨牙区的咬合力分布情况,分析咬合力重心位置的变化。结果种植组全牙列咬合力明显低于天然牙列,磨牙区咬合力也明显低于天然牙列,但是双尖牙区咬合力明显高于天然牙列,咬合力重心位置明显前移,左右牙列咬合力均衡。结论全口无牙颌应用种植固定修复后,双尖牙区承担了更多的咬合力。     

Comparison of Survival of Patients With Lung Cancer Between Elderly (greater double equals70) and Younger (70>) Age Groups

Results of radiotherapy for lung cancer in the elderly werecompared with those in younger patients. A total of 129 patientswere treated by radiation therapy with or without chemotherapy.Fifty-six patients (43.4%) were 70 years old or more (elderlygroup) at the time of treatment, and the remaining 73 patientswere below age 70 (younger group). Treatment results in the elderly group were nearly the sameas those in the younger group in all stages of the disease.Survival time was longer for patients with performance status(PS) of 0 to 2 than for those with PS 3 or 4 regardless of age(p < 0.05). The survival time of the elderly group was nearlythe same as that of the younger group for squamous cell carcinoma,but somewhat shorter for adenocarcinoma although the differencewas not statistically significant. There was no difference insurvival between the two groups when they were treated by combinedradiation therapy and chemotherapy. Our results suggest thatelderly patients can be treated as safely as younger patientsby radiotherapy alone or combined radiation therapy and chemotherapy.     

Increased level/dose ratio of amphotericin-B in premature infants with renal failure

We introduced continuous intravenous infusion of amphotericin-B (AMPH-B) to extremely low birth-weight (ELBW) infants (< 1000 g) with or without renal failure as a single agent for treating definite or probable systemic candidiasis. The species of Candida isolated from blood or tracheal aspirate or urine were C. albicans in seven infants, C. glablata in two, C. tropicalis in one and C. parapsilosis in one. The minimal inhibitory concentrations (MIC) of AMPH-B required against these isolates were less than 0.2 μg/mL except for that against one strain of C. albicans (0.78 μg/mL). Serum AMPH-B levels were 0.31-0.78 (0.51 ± 0.14) μg/mL when doses of 0.2-0.55 (0.32 ± 0.11) mg/kg per day were being administered. The serum level was higher than the MIC of each isolate in all but one infant who died of disseminated intravascular coagulation and Candida pneumonia. Another infant died of congenital heart disease. The other nine infants survived. The serum level showed no correlation with the daily dose. The ratio of the serum level to the daily dose (L/D ratio) showed a significant correlation to serum creatinine (r = 0.787) and the linear regression curve followed the equation: L/D ratio = 0.223 x serum creatinine + 1.11 (P < 0.01). Few adverse effects due to AMPH-B were noted. Our data may give a simple reference to serum AMPH-B levels during continuous intravenous infusion from the dose and the serum creatinine level.     

A Left Free-Wall, Decrementally Conducting, Atrioventricular (Mahaim) Fiber: Diagnosis at Electrophysiological Study and Radiofrequency Catheter Ablation Guided by Direct Recording of a Mahaim Potential

A 64-year-old female with Wolff-Parkinson-White syndrome and an ECG demonstrating a rigbt posterolateral accessory pathway was referred for electrophysiological study. During electrophysiological testing two AV pathways were identified: a right posterolateral pathway that displayed conventional electrophysiological properties: and a left free-wall pathway tbat conducted only anterogradely and demonstrated decremental properties. Two separate wide complex tachycardias were induced that utilized the left free-wall pathway anterogradely and either the AV node or the right posterolateral accessory pathway retrogradely. A discrete electrical potential on the free wall of the mitral an-nulus was identified during tachycardia and was utilized to facilitate mapping and ablation.     

Heparanase expression in both normal endometrium and endometrial cancer

The aim of this study was to investigate the relationship between heparanase expression and prognostic factors in endometrial cancer, as well as the relationship between heparanase expression during phases of the normal endometrial cycle. Immunohistochemical analysis of 166 endometrial cancers and 34 normal endometria in various phases of growth was performed. The heparanase expression in the late-proliferative phase of normal endometria was found to be significantly higher than in either the early-proliferative or the secretory phases (P= .012 and P= .044, respectively). Heparanase expression was also significantly higher in endometrial cancer patients with tumors of an advanced FIGO stage (P= .0003) and high FIGO grade (P= .004) and with cancers showing either deep myometrial invasion (P= .023), lymph node metastasis (P= .006), lymphvascular space involvement (P= .048), or positive peritoneal cytology (P= .010). The disease-free and overall survival rates of patients with intense heparanase expression were significantly lower than those of patients with absent or moderate heparanase expression (P= .004 and P= .002, respectively). Heparanase may participate in normal endometrial remodeling and can serve as an indicator of the aggressive potential and poor prognosis of endometrial cancers.